OR WAIT null SECS
© 2021 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Company News Release
Drug developers, healthcare providers, insurance companies, and others involved in the delivery of healthcare in the United States are uncertain about the benefits of a risk evaluation program introduced three years ago by the Food and Drug Administration (FDA), according to the Tufts Center for the Study of Drug Development.
Key findings of Tufts CSDD’s assessment of the Risk Evaluation & Mitigation Strategy (REMS) program, the first systematic look at the initiative since the FDA introduced it in 2008, were reported in the January/February Tufts CSDD Impact Report, released today.
"A majority of the organizations told us they felt the REMS program needs a major overhaul, and said that a REMS is a poor substitute for other improvements needed system-wide in drug education, communication, use monitoring, patient access, and delivery of care," said Christopher-Paul Milne, associate director at Tufts CSDD, who conducted the assessment.
Drug developers must create a REMS as part of a new product approval application, and sometimes for a previously approved product, when the FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks.
According to Milne, "Most respondents said it is virtually impossible to measure the benefits of a REMS, compared to its burdens on patient access and cost of health care delivery, for a newly approved drug, and that even for an already-approved drug, it would likely require two years or more to effectively conduct such an assessment."
Among other findings developed by the survey were the following:
Milne noted that the REMS program will likely impact a growing number of healthcare stakeholders as the number of products with REMS expands in coming years.